Pathy's Principles and Practice of Geriatric Medicine

92 92. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low‐dose interleukin‐11 in patients with bone marrow failure. J Clin Oncol. 2001; 19(21):4165–4172. doi:10.1200/JCO.2001.19.21.4165

93 93. Kuter DJ, Bussel JB, Lyons RM, et al. Effi Cacy of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura: A Double‐Blind Randomised Controlled Trial. Vol 371.; 2008.

94 94. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower‐risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010; 28(3):437–444. doi:10.1200/JCO.2009.24.7999

95 95. Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010; 116(17):3163–3170. doi:10.1182/blood‐2010‐03‐274753

96 96. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, non‐peptide thrombopoietin receptor agonist. Blood. 2007; 109(11):4739–4741. doi:10.1182/blood‐2006‐11‐057968

97 97. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol. 2002; 20(10):2429–2440. doi:10.1200/JCO.2002.04.117

98 98. Fenaux P, Mufti GJ, Hellstrom‐Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher‐risk myelodysplastic syndromes: a randomised, open‐label, phase III study. Lancet Oncol. 2009; 10(3):223–232. doi:10.1016/S1470‐2045(09)70003‐8

99 99. Lübbert M, Suciu S, Baila L, et al. Low‐dose decitabine versus best supportive care in elderly patients with intermediate‐ or high‐risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the european organisation for rese. J Clin Oncol. 2011; 29(15):1987–1996. doi:10.1200/JCO.2010.30.9245

100 100. Zeidan AM, Davidoff AJ, Long JB, et al. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016; 175(5):829–840. doi:10.1111/bjh.14305

101 101. Prébet T, Gore SD, Esterni B, et al. Outcome of high‐risk myelodysplastic syndrome after azacitidine Treatment failure. J Clin Oncol. 2011; 29(24):3322–3327. doi:10.1200/JCO.2011.35.8135

102 102. Muffly L, Pasquini MC, Martens M, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017; 130(9):1156–1164. doi:10.1182/blood‐2017‐03‐772368

Текст предоставлен ООО «ЛитРес».

Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.

Безопасно оплатить книгу можно банковской картой Visa, MasterCard, Maestro, со счета мобильного телефона, с платежного терминала, в салоне МТС или Связной, через PayPal, WebMoney, Яндекс.Деньги, QIWI Кошелек, бонусными картами или другим удобным Вам способом.